The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...

ONAPGOis the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Laxxon Medical, a leading pharmaceutical technology company pioneering a new generation of advanced drug ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Q1 2025 Earnings Call Transcript February 10, 2025 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.39 EPS, expectations were $-0.42. Chris Anzalone: Thanks, Vince.

A HUSBAND from Christchurch has put into writing the experience of his wife living with Parkinson’s in his debut book. Laurence Phillips lives in the town with his wife Estelle Phillips, who has had ...

MALVERN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ('Annovis' or the 'Company'), a late-stage clinical ...

People's ability to interpret emotions or focus on performing a task is reduced by short-term exposure to particulate matter ...